| scholarly article | Q13442814 |
| P2093 | author name string | Ho Yeong Lim | |
| Heesue Kim | |||
| P2860 | cites work | NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN | Q24292919 |
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography. | Q33798661 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| G1 cell-cycle control and cancer | Q34368858 | ||
| Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. | Q34506608 | ||
| Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer | Q34560933 | ||
| Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma | Q34842280 | ||
| Targeting the epidermal growth factor receptor for cancer therapy | Q34863779 | ||
| The cell cycle: accelerators, brakes, and checkpoints | Q35694554 | ||
| Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment | Q36395200 | ||
| On the TRAIL to therapeutic intervention in liver disease | Q36863153 | ||
| Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. | Q37276117 | ||
| Pathogenesis of hepatocellular carcinoma and molecular therapies. | Q37456002 | ||
| KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition. | Q43223784 | ||
| Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum | Q44262333 | ||
| Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma | Q46505107 | ||
| Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. | Q46848169 | ||
| Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. | Q54594283 | ||
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma | Q80112177 | ||
| Systemic treatment of hepatocellular carcinoma | Q80198016 | ||
| Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib | Q80307760 | ||
| Promoter methylation of the PTEN gene is a common molecular change in breast cancer | Q80403566 | ||
| Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma | Q80595806 | ||
| P433 | issue | 12 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1563-1568 | |
| P577 | publication date | 2011-11-29 | |
| P1433 | published in | Journal of Korean Medical Science | Q24039955 |
| P1476 | title | Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways | |
| P478 | volume | 26 |
| Q39235281 | An overview of quinoline as a privileged scaffold in cancer drug discovery |
| Q37067080 | Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related hepatocellular carcinoma in the population of North China |
| Q90169422 | Dracohodin Perochlorate Stimulates Fibroblast Proliferation via EGFR Activation and Downstream ERK/CREB and PI3K/Akt/mTOR Pathways In Vitro |
| Q36319689 | EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation |
| Q36729450 | HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. |
| Q54171446 | Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations. |
| Q92615262 | Yiqi Chutan Tang Reduces Gefitinib-Induced Drug Resistance in Non-Small-Cell Lung Cancer by Targeting Apoptosis and Autophagy |
Search more.